Ocugen Inc (OCGN) — Titan Protect Analysis

OCGN

Ocugen Inc

Healthcare · ·

$1.28

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$445M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.60

Based on estimated future earnings — lower means cheaper

Rev Growth

+3.5%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-660.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+681% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Ocugen Inc

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c

https://www.ocugen.com

Country: United States Employees: 116 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.215

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0260

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.178

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-13.1%

Historical annualised return based on price data

Max Drawdown

-73.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.31

Significantly more volatile than the market

52W High

$2.73

53% below the year high

52W Low

$0.86

50% above the year low

Avg Volume

8,754,114

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.24

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

573.58

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,163.7%

Profit from core operations before interest and tax

Free Cash Flow

$-33,665,624

Negative — the business is spending more than it generates

Revenue (TTM)

$4M

Total revenue over the last 12 months

Net Income

$-71,673,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$22.00

Target Median

$10.00

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go